Idera Pharmaceuticals, Inc. Enters into Agreement With National Cancer Institute to Evaluate Use of TLR Antagonists for the Treatment of Genetically Defined Lymphomas
Published: Aug 29, 2013
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it has entered into a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Cancer Institute (NCI) to evaluate the Company’s Toll-like receptor (TLR) antagonists as a potential approach to the treatment of certain genetically defined B-cell lymphomas.
Help employers find you! Check out all the jobs and post your resume.